Skip to main content

Table 2 RR and study power in LRFS, DRFS, DFS, and OS in BCS

From: Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis

Study

pCR, n (%)

LR

DR

DFS

OS

Overall event/event

RR

Power

Overall event/event

RR

Power

Overall event/event

RR

Power

Overall event/event

RR

Power

Caudle 2012 [19]

124 (20.8)

37/3

0.34

0.605

NA

NA

NA

NA

NA

NA

NA

NA

NA

Bonadonna 2002 [20]

7 (3.3)

8/0

1.52

0.106

NA

NA

NA

NA

NA

NA

NA

NA

NA

Fastner 2014 [17]

15 (14.0)

6/0

0.45

0.247

NA

NA

NA

NA

NA

NA

NA

NA

NA

Noh 2014 [25]a

102 (39.2)

13/2

0.28

0.476

18/1

0.09

0.911

55/3

0.09

1

9/0

0.08

0.751

Shen 2004 [16]a

4 (12.1)

5/0

0.55

0.195

9/0

0.32

0.345

NA

NA

NA

NA

NA

NA

Cho 2013 [22]

38 (30.6)

6/0

0.17

0.482

16/1

0.15

0.723

21/1

0.11

0.897

15/4

0.82

0.066

Jimbo 2014 [21]

63 (32.5)

5/2

1.39

0.065

NA

NA

NA

NA

NA

NA

NA

NA

NA

Yamazaki 2015 [26]a

56 (25.8)

14/6

2.16

0.276

NA

NA

NA

NA

NA

NA

NA

NA

NA

Rouzier 2001 [10]

28 (10.9)

41/2

0.42

0.328

71/4

0.49

0.441

NA

NA

NA

NA

NA

NA

Mclntosh 2003 [18]

18 (40.9)

1/0

0.47

0.138

NA

NA

NA

NA

NA

NA

NA

NA

NA

Beriwal 2006 [24]a

37 (24.2)

21/4

0.74

0.095

NA

NA

NA

NA

NA

NA

NA

NA

NA

total

492 (22.4)

157/19

0.59

0.933

114/6

0.27

1

76/4

0.09

1

24/4

0.36

0.589

  1. Abbreviation: RR risk ratio, LR local recurrence, DR distance recurrence, DFS disease-free survival, OS overall survival, pCR pathology complete response, NA not available
  2. aMeans the definition of pCR was the absence of invasive component in the primary breast tumor, irrespective of pathological axillary node status